125
Participants
Start Date
April 11, 2021
Primary Completion Date
July 2, 2025
Study Completion Date
July 2, 2025
SAR444881
Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Pembrolizumab
Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Cetuximab
Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Carboplatin
Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
Pemetrexed
Pharmaceutical form: Powder for concentrate for solution for infusion or concentrate for solution for infusion; Route of administration: Intravenous
Mid Florida Hematology and Oncology Center- Site Number : 8400006, Orange City
Clermont Oncology Center- Site Number : 8400005, Clermont
Norton Cancer Institute - Downtown Women's Cancer Center- Site Number : 8400004, Louisville
Mercy Cancer Center - MercyOne Richard Deming Cancer Center- Site Number : 8400011, Des Moines
Mayo Clinic Hospital Rochester- Site Number : 8400007, Rochester
University of Colorado- Site Number : 8400012, Aurora
City of Hope Comprehensive Cancer Center- Site Number : 8400002, Duarte
Investigational Site Number : 3760004, Haifa
Investigational Site Number : 3760001, Petah Tikva
Investigational Site Number : 3760003, Ramat Gan
Investigational Site Number : 3760002, Tel Aviv
Investigational Site Number : 3760005, Jerusalem
Mayo Clinic Hospital- Site Number : 8400003, Phoenix
Smilow Cancer Center at Yale-New Haven- Site Number : 8400001, New Haven
Investigational Site Number : 1240001, Barrie
Investigational Site Number : 1240003, Sherbrooke
Investigational Site Number : 8260003, London
Investigational Site Number : 8260002, Leeds
Lead Sponsor
Sanofi
INDUSTRY